Phaseline

Companies › Nuvectis Pharma

Nuvectis Pharma: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NXP900
SRC family kinase inhibitor
SRCPhase 1EGFR Mutation Positive Non-small Cell Lung Cancer; Advanced Solid Tumor; ALK PositiveDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07315113NXP900Phase 1EGFR Mutation Positive Non-small Cell Lung CancerOncologyDec 2026
NCT05873686NXP900Phase 1Advanced Solid TumorOncologyMar 2027
NCT07784959NXP900Phase 1ALK PositiveOncologyAug 2027

From the company's SEC filings

Cash of $141m on 2026-09-30; operating cash outflow about $49m a year; runway about 35 months at that burn, to Aug 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SRC (1)

Companies with the same targets

Turning Point Therapeutics The Skin Center Dermatology Group Almirall

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.